pdufa.bio

ZEVASKYN (prademagene zamikeracel)

Page updated ·next FDA decision on the calendar ·Data as of Oct 11, 2026 9:31 PM ET

ZEVASKYN (prademagene zamikeracel) The FDA approved it on Apr 29, 2025. 1 FDA decision on record below. Every date links its source.

ABEO catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Apr 29, 2025 ✓ ApprovedABEO

Questions

When is ZEVASKYN (prademagene zamikeracel)'s next FDA decision or readout?

No upcoming catalyst is on our calendar for ZEVASKYN (prademagene zamikeracel); 1 FDA decision is on record below.

What happened at ZEVASKYN (prademagene zamikeracel)'s most recent FDA decision?

On Apr 29, 2025 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has ZEVASKYN (prademagene zamikeracel) been approved by the FDA?

Yes. The FDA approved an application for ZEVASKYN (prademagene zamikeracel) on Apr 29, 2025; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.